Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present At American Society of Hematology Annual Meeting 2021
December 13, 2021 at 07:00 am EST
Share
Sutro Biopharma, Inc. announced that its research collaborators at the Fred Hutchinson Cancer Research Center presented nonclinical data of STRO-002 and STRO-001 in two oral presentations at the 63rd American Society of Hematology Annual Meeting in Atlanta, Georgia. The research was conducted by investigators from the laboratory of Soheil Meshinchi, M.D., Ph.D., Professor, Clinical Research Division at Fred Hutchinson Cancer Research Center and Professor, Division of Pediatric Hematology-Oncology at the University of Washington School of Medicine. Nonclinical data was presented by Quy Le, Ph.D., Staff Scientist, Meshinchi Lab, Fred Hutchinson Cancer Research Center on Sutro's folate receptor alpha (FOLR1 or FolRa) -targeting antibody-drug conjugate, STRO-002, as a potential therapeutic in a rare pediatric acute myeloid leukemia subtype expressing FolRa. RNA-sequencing data demonstrated that FOLR1 is uniquely expressed in CBFA2T3-GLIS2 fusion (CBF/GLIS) AML and absent in other AML subtypes and normal hematopoietic cell populations. Data from an AML cell line engineered to express FOLR1 and CBF/GLIS-transduced cord blood hematopoietic stem/progenitor cells (CB HSPCs) demonstrated high cytotoxicity of STRO-002. In FOLR1 positive and CBF/GLIS-transduced CB HSPCs xenograft models, STRO-002 demonstrated potent activity that led to complete leukemia clearance. Nonclinical data was also presented by Quy Le, Ph.D., Staff Scientist, Meshinchi Lab, Fred Hutchinson Cancer Research Center on Sutro's CD74-targeting ADC, STRO-001, as a potential therapeutic in AML and acute lymphoblastic leukemia (ALL). Data from AML and ALL cell lines, as well as from nonclinical xenograft models, demonstrated robust in vitro and in vivo cytotoxicity of STRO-001 on cells expressing high- to -moderate levels of CD74, with no cytotoxicity observed in cells without CD74 expression. Potent anti-leukemia activity was also demonstrated in three primary AML patient samples with varied CD74 expression levels.
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Companyâs advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.